SHANGHAI YIZHONG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.42 CNY | -10.90% |
|
-4.05% | -41.53% |
| Sales 2022 | 235.96 1.71K 19.68K | Sales 2023 | 360.25 2.61K 30.05K | Capitalization | 10.13B 73.35B 845B |
|---|---|---|---|---|---|
| Net income 2022 | 143M 1.04B 11.93B | Net income 2023 | 162M 1.17B 13.51B | EV / Sales 2022 | 3,77,85,049 x |
| Net cash position 2022 | 1.13B 8.17B 94.08B | Net cash position 2023 | 1.2B 8.66B 99.79B | EV / Sales 2023 | 2,47,97,961 x |
| P/E ratio 2022 |
70.5
x | P/E ratio 2023 |
62.7
x | Employees | 304 |
| Yield 2022 |
0.43% | Yield 2023 |
0.48% | Free-Float | 40.19% |
More Fundamentals
* Assessed data
More news
| 1 day | -10.90% | ||
| 1 week | -4.05% | ||
| Current month | -12.69% | ||
| 1 month | -12.69% | ||
| 3 months | -23.16% | ||
| 6 months | -32.27% | ||
| Current year | -41.53% |
1 week
36.88
42.18
1 month
36.8845.49
Current year
36.5566.80
1 year
36.5582.60
3 years
25.68132.94
5 years
25.68132.94
10 years
25.68132.94
| Managers | Title | Age | Since |
|---|---|---|---|
Duan Li
FOU | Founder | 84 | 10/09/10 |
Jin Song Zhou
CEO | Chief Executive Officer | 56 | 10/09/10 |
Ruo Yun Pan
CHM | Chairman | 43 | 01/17/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jin Song Zhou
CEO | Chief Executive Officer | 56 | 10/09/10 |
Duan Li
FOU | Founder | 84 | 10/09/10 |
Jing Sun
BRD | Director/Board Member | 47 | 01/09/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.32% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 37.42 | -10.90% | 4,782,102 |
| 29/24/29 | 42 | +4.30% | 1,767,158 |
| 26/24/26 | 40.27 | +1.82% | 1,637,657 |
| 25/24/25 | 39.55 | -.--% | 816,737 |
| 24/24/24 | 39.55 | -0.95% | 816,768 |
End-of-day quote Shanghai S.E., April 30, 2024
More quotes
Shanghai Yizhong Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development and industrialization of new and improved anti-tumor drugs. The Company's main products include paclitaxel micelles, docetaxel micelles and cabazitaxel micelles. Paclitaxel micelles are products under development that have been submitted for registration and marketing applications, and their indications are non-small cell lung cancer. Docetaxel micelles and cabazitaxel micelles are products under development in the pre-clinical research stage.
Sector
Pharmaceuticals
Calendar
16/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -41.53% | 818M | |
| +12.55% | 9.06B | |
| -12.75% | 4.96B | |
| +42.38% | 4.47B | |
| +5.23% | 3.9B | |
| +20.59% | 2.41B | |
| -19.05% | 2.41B | |
| -28.72% | 2.23B | |
| +11.13% | 2.02B | |
| +3.94% | 1.65B |
- Stock Market
- Equities
- 688091 Stock
